Bird C R, Drayer B P, Medina M, Rekate H L, Flom R A, Hodak J A
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013.
Radiology. 1988 Oct;169(1):123-6. doi: 10.1148/radiology.169.1.3420247.
A prospective study was conducted in 15 pediatric patients who had undergone resection of intracranial tumors. The object of the study was to determine the safety and efficacy of magnetic resonance (MR) imaging performed after the administration of gadolinium diethylenetriamine-pentaacetic acid (Gd-DTPA) in evaluating residual or recurrent tumor. Precontrast T1-weighted, intermediate, and T2-weighted images were obtained at a field strength of 1.5 T. Gd-DTPA was then injected intravenously in a dose of 0.1 mmol per kilogram of body weight. T1-weighted images were obtained within 5 minutes after the injection, intermediate and T2-weighted images were obtained 10 minutes after the injection, and T1-weighted images were obtained approximately 20 minutes after the injection. None of the patients experienced allergic reactions or other side effects. Physical examination findings and laboratory values were unchanged after the Gd-DTPA-enhanced examination. In six patients, contrast-enhanced images depicted tumor not suspected on nonenhanced images. In four other patients, enhanced images provided better definition of the tumor core. The images of one patient with a brain stem tumor showed no evidence of enhancement. Pre- and postcontrast images of three previously treated patients showed no evidence of tumor. Gd-DTPA appears to be a safe and effective contrast agent for MR imaging and provides a more accurate method of imaging in the follow-up of brain tumors in pediatric patients.
对15例接受颅内肿瘤切除术的儿科患者进行了一项前瞻性研究。该研究的目的是确定静脉注射钆喷酸葡胺（Gd-DTPA）后进行磁共振（MR）成像在评估残留或复发性肿瘤方面的安全性和有效性。在1.5T场强下获取注射造影剂前的T1加权、中等加权和T2加权图像。然后以每千克体重0.1mmol的剂量静脉注射Gd-DTPA。注射后5分钟内获取T1加权图像，注射后10分钟获取中等加权和T2加权图像，注射后约20分钟获取T1加权图像。所有患者均未出现过敏反应或其他副作用。Gd-DTPA增强检查后，体格检查结果和实验室值均未改变。在6例患者中，增强图像显示出非增强图像上未怀疑的肿瘤。在另外4例患者中，增强图像能更好地显示肿瘤核心。1例脑干肿瘤患者的图像未显示增强迹象。3例先前接受过治疗的患者的注射造影剂前后图像均未显示肿瘤迹象。Gd-DTPA似乎是一种用于MR成像的安全有效的造影剂，并且为儿科患者脑肿瘤的随访提供了一种更准确的成像方法。
